Failure to identify modifiers of NEBULIN-related nemaline myopathy in two pre-clinical models of the disease
AffiliationUniv Arizona, Dept Physiol
MetadataShow full item record
PublisherCOMPANY BIOLOGISTS LTD
CitationQiu, B., Ruston, J., Granzier, H., Justice, M. J., & Dowling, J. J. (2019). Failure to identify modifiers of NEBULIN-related nemaline myopathy in two pre-clinical models of the disease. Biology Open, 8(9), bio044867.
RightsCopyright © 2019. Published by The Company of Biologists Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed.
Collection InformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at firstname.lastname@example.org.
AbstractNemaline myopathy is a rare neuromuscular disorder that affects 1 in 50,000 live births, with prevalence as high as 1 in 20,000 in certain populations. 13 genes have been linked to nemaline myopathy (NM), all of which are associated with the thin filament of the muscle sarcomere. Of the 13 associated genes, mutations in NEBULIN (NEB) accounts for up to 50% of all cases. Currently, the disease is incompletely understood and there are no available therapeutics for patients. To address this urgent need for effective treatments for patients affected by NM, we conducted a large scale chemical screen in a zebrafish model of NEB-related NM and an N-ethyl-N-nitrosourea (ENU)-based genetic screen in a mouse model of NEB exon 55 deletion, the most common NEB mutation in NM patients. Neither screen was able to identify a candidate for therapy development, highlighting the need to transition from conventional chemical therapeutics to gene-based therapies for the treatment of NM.
NoteOpen access journal
VersionFinal published version
SponsorsUnited States Department of Health & Human Services - National Institutes of Health (NIH) - USA [R01AR053897]; HSBC Bank Canada catalyst grant from the Hospital for Sick Children; operating grant from A Foundation Building Strength
- Deleting exon 55 from the nebulin gene induces severe muscle weakness in a mouse model for nemaline myopathy.
- Authors: Ottenheijm CA, Buck D, de Winter JM, Ferrara C, Piroddi N, Tesi C, Jasper JR, Malik FI, Meng H, Stienen GJ, Beggs AH, Labeit S, Poggesi C, Lawlor MW, Granzier H
- Issue date: 2013 Jun
- Neb: a zebrafish model of nemaline myopathy due to nebulin mutation.
- Authors: Telfer WR, Nelson DD, Waugh T, Brooks SV, Dowling JJ
- Issue date: 2012 May
- Thin filament length dysregulation contributes to muscle weakness in nemaline myopathy patients with nebulin deficiency.
- Authors: Ottenheijm CA, Witt CC, Stienen GJ, Labeit S, Beggs AH, Granzier H
- Issue date: 2009 Jul 1
- Nebulin nemaline myopathy recapitulated in a compound heterozygous mouse model with both a missense and a nonsense mutation in Neb.
- Authors: Laitila JM, McNamara EL, Wingate CD, Goullee H, Ross JA, Taylor RL, van der Pijl R, Griffiths LM, Harries R, Ravenscroft G, Clayton JS, Sewry C, Lawlor MW, Ottenheijm CAC, Bakker AJ, Ochala J, Laing NG, Wallgren-Pettersson C, Pelin K, Nowak KJ
- Issue date: 2020 Feb 17
- Identification of 45 novel mutations in the nebulin gene associated with autosomal recessive nemaline myopathy.
- Authors: Lehtokari VL, Pelin K, Sandbacka M, Ranta S, Donner K, Muntoni F, Sewry C, Angelini C, Bushby K, Van den Bergh P, Iannaccone S, Laing NG, Wallgren-Pettersson C
- Issue date: 2006 Sep